A prospective observational study to investigate the safety of SARS-CoV-2 vaccine in patients with lung cancer who are treated or will be treated with anticancer medication (OLCSG2102)
Not Applicable
- Conditions
- ung cancer
- Registration Number
- JPRN-UMIN000043918
- Lead Sponsor
- Iwakuni Clinical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with a history of developing COVID-19 2) Patients with a history of SARS-CoV-2 vaccination 3) Patients who think that it is inappropriate for their doctor to inoculate SARS-CoV-2 vaccine 4) Patients with an estimated prognosis within 2 months
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method